Resochin
Categoria
Resochin Marchi, Resochin Analoghi
- 3377 RP opalate
- Amokin
- Aralen
- Aralen HCl
- Arechin
- Arthrochin
- Artrichin
- Avlochlor
- Avloclor
- Bemaco
- Bemaphate
- Bemasulph
- Benaquin
- Bipiquin
- Capquin
- Chemochin
- Chingamin
- Chloraquine
- Chlorochin
- Chlorochine
- Chloroquina
- Chloroquine (VAN)
- Chloroquine Phosphate
- Chloroquinium
- Chlorquin
- Cidanchin
- Clorochina
- Cocartrit
- Delagil
- Dichinalex
- Elestol
- Gontochin
- Heliopar
- Hydroxychloroquine Sulfate
- Imagon
- Iroquine
- Klorokin
- Lapaquin
- Malaquin
- Malaren
- Malarex
- Mesylith
- Neochin
- Nivachine
- Nivaquine
- Nivaquine B
- Nivaquine [as sulfate]
- Pfizerquine
- Plaquenil
- Quinachlor
- Quinagamin
- Quinagamine
- Quinercyl
- Quingamine
- Quinilon
- Quinoscan
- Resochen
- Resochin
- Resoquina
- Resoquine
- Reumachlor
- Reumaquin
- Roquine
- Sanoquin
- Silbesan
- Siragan
- Solprina
- Sopaquin
- Tanakan
- Tresochin
- Trochin
Resochin Marchi miscela
Resochin Formula chimica
C18H26ClN3
Resochin RX link
http://www.rxlist.com/cgi/generic2/hquine2.htm
Resochin FDA foglio
Resochin DMS (foglio di materiale di sicurezza)
Resochin Sintesi di riferimento
Nessuna informazione disponibile
Resochin Peso molecolare
319.872 g/mol
Resochin Temperatura di fusione
289 oC
Resochin H2O Solubilita
10,6 mg / L
Resochin Stato
Solid
Resochin LogP
4.474
Resochin Forme di dosaggio
Compressa
Resochin Indicazione
Per il trattamento soppressivo e per attacchi acuti di malaria a causa di P. vivax, P.malariae, P. ovale, e ceppi sensibili di P. falciparum, l'agente di seconda linea nel trattamento dell'artrite reumatoide
Resochin Farmacologia
Clorochina è l'anti droga prototipo di malaria, più ampiamente utilizzati per trattare tutti i tipi di malaria, fatta eccezione per la malattia causata da Plasmodium falciparum resistente alla clorochina. È altamente efficace contro eritrocitaria forme di Plasmodium vivax, Plasmodium ovale e Plasmodium malariae, ceppi sensibili di Plasmodium falciparum e gametociti di Plasmodium vivax. Essendo alcalino, il farmaco raggiunge concentrazioni elevate all'interno dei vacuoli alimentari del parassita e aumenta il pH. Si trova a indurre una rapida aggregazione del pigmento. Clorochina inibisce la polimerasi parassita eme enzima che converte l'eme tossici in non tossico hemazoin, provocando l'accumulo di eme tossici all'interno del parassita. Si può anche interferire con la biosintesi degli acidi nucleici.
Resochin Assorbimento
Completamente assorbito dal tratto gastrointestinale
Resochin Tossicita
Nessuna informazione disponibile
Resochin Informazioni paziente
PATIENT INFORMATION
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Resochin Atto interessato organismi
Plasmodium
